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Introduction {#acn350957-sec-0001}
============

Next‐generation sequencing (NGS) including both targeted gene panels and exome sequencing has become a central component of the diagnostic evaluation of individuals with a neurologic disorder of unknown origin.[1](#acn350957-bib-0001){ref-type="ref"}, [2](#acn350957-bib-0002){ref-type="ref"} Exome sequencing has shown success in phenotypically diverse cohorts, including the leukodystrophies, a broad class of genetic disorders that affect the white matter of the central nervous system (CNS).[2](#acn350957-bib-0002){ref-type="ref"}, [3](#acn350957-bib-0003){ref-type="ref"}

Leukodystrophies are diverse in origin and highly heterogeneous in presentation and disease course, making diagnosis challenging. Until recently, the probability of obtaining a definitive molecular diagnosis was less than 50% over 5 years[2](#acn350957-bib-0002){ref-type="ref"} and despite increases of up to threefold in diagnostic efficacy, many cases remain unsolved. Previously, we reported on a cohort of 191 families with a suspected leukodystrophy, of which 71 were persistently unsolved despite targeted molecular and enzymatic testing and 19 were lost to follow‐up.[1](#acn350957-bib-0001){ref-type="ref"} Trio‐or‐greater exome sequencing analysis resolved 42% (30/71) of unsolved cases, which, in combination with standard of care approaches, yielded a 77% overall diagnostic rate from 172 families available for testing. This was a substantial increase over the historical norms,[2](#acn350957-bib-0002){ref-type="ref"} but left at least 23% persistently unsolved.[1](#acn350957-bib-0001){ref-type="ref"}

Genome sequencing has the potential to detect a wide variety of variant types, including single‐nucleotide variants and indels (out‐performing exome sequencing in protein‐coding regions), copy number variants (CNV),[4](#acn350957-bib-0004){ref-type="ref"} repeat expansions,[5](#acn350957-bib-0005){ref-type="ref"} and detection of pathogenic nonprotein‐coding variation that is missed by other NGS approaches. We pursued genome sequencing on the remaining 41 persistently unsolved families to assess the potential value of genome sequencing diagnostics in a pediatric neurological disease cohort.

Methods {#acn350957-sec-0002}
=======

Recruitment {#acn350957-sec-0003}
-----------

Affected individuals were referred to the Myelin Disorders Bioregistry Project (MDBP) for unsolved leukoencephalopathy of presumed genetic etiology between 1 August 2009 to 31 July 2013, as previously described.[1](#acn350957-bib-0001){ref-type="ref"} The study had approval from the institutional review boards at collaborating institutions.

Clinical and neuroimaging descriptions are available on request. All individuals had abnormal white matter identified by neuroimaging, suggestive of a leukodystrophy. Symptom onset ranged from birth to 19 years. Ethnicities varied and included individuals of mixed and northern European descent, as well as African American, Arabian, African, Asian, and Latin American origin.[1](#acn350957-bib-0001){ref-type="ref"}

Genome sequencing and analysis {#acn350957-sec-0004}
------------------------------

Genome sequencing was performed at Illumina Inc., San Diego on an Illumina 2000 using 2 x 125 nucleotide paired‐end reads. Dual analyses were run in parallel for each sample. In one, reads were aligned to the reference human genome (GRCh37) using the Burrows‐Wheeler Aligner (BWA) software package and pedigree informed variant calling was performed using the GATK HaplotypeCaller v3.7.[6](#acn350957-bib-0006){ref-type="ref"} Variant annotation was performed using SnpEff v4.3m.[7](#acn350957-bib-0007){ref-type="ref"} This analysis used a custom variant annotation and interpretation interface to identify possible causal variants. In the other analysis, samples were processed using the Illumina Secondary Analysis Software v5.11.0 (Northstar v5 release), aligned to the reference human genome (GRCh37). Candidate variants were identified using a custom‐built variant interpretation engine. In both analyses, variants were triaged and prioritized by minor allele frequency, conservation, genotype, inheritance, disease‐association, consequence, and predicted pathogenicity. Candidate splice‐altering variants were validated using a minigene splicing assay (Appendix [S1](#acn350957-sup-0001){ref-type="supplementary-material"}).[8](#acn350957-bib-0008){ref-type="ref"}

Assessment of Variants {#acn350957-sec-0005}
----------------------

Putatively causal variants were assessed as per the American College of Medical Genetics (AGMC) guidelines.[9](#acn350957-bib-0009){ref-type="ref"} Cases with variants in known disease genes meeting the ACMG criteria for pathogenic or likely pathogenic, and whose clinical features were concordant with the established gene--disease relationship (including magnetic resonance imaging (MRI) patterns) were classified as resolved. Candidate variants in potentially novel disease genes were submitted to GeneMatcher.

Results {#acn350957-sec-0006}
=======

Forty‐one families that remained without a molecular etiology after exome sequencing received genome sequencing (Fig. [1](#acn350957-fig-0001){ref-type="fig"}A). The mean read depth in probands was 34X and on average, 91% of the genome had coverage depth greater than 20X (Appendix [S1](#acn350957-sup-0001){ref-type="supplementary-material"}). Genome sequencing resulted in a molecular diagnosis for 14 families (34%) (Table [1](#acn350957-tbl-0001){ref-type="table"}). Nine diagnoses were achieved through improvements in variant curation or novel disease‐associated genes described since the exome sequencing analysis. Five diagnoses were achieved through identification of CNVs (three cases), deep intronic variants (one case), and variants in technically difficult regions (one case). One case was considered clinically resolved following multidisciplinary review.

![Myelin Disorders Bioregistry Project Unsolved Cohort and Challenging Variants in Known Leukodystrophy Genes. (A) The initial "unsolved" cohort consisted of 191 families. 101 were diagnosed by standard of care (SoC) methodologies, 71 of the remaining families underwent exome sequencing, while 19 were excluded due to lack of DNA or inability to access the family trio for NGS testing. The genome sequencing cohort consisted of 41 families, 14 of which were solved. (B) Variants in *GJC2* (OMIM:608803) were identified in LD_0617 and are causative of Pelizaeus‐Merzbacher‐like disease (OMIM:608804). The 13bp paternally inherited duplication, c.916_928dupGCCTCCGCCCCCG, p.Ala310fs in *GJC2*, was previously undetected by exome sequencing due to a lack of coverage in this region.[1](#acn350957-bib-0001){ref-type="ref"} (C) The duplication lies in the middle of a 110 nucleotide block of a \~ 95% GC‐rich region and was identified in the affected individual and father on genome sequencing, where it is indicated by a green rectangle. (D) Sanger chromatogram confirming the presence of the c.916_928dupGCCTCCGCCCCCG variant in the LD_0617 proband. The duplicated sequence is indicated in red with the second copy in LD_0617 bold and underlined.](ACN3-7-144-g001){#acn350957-fig-0001}

###### 

Clinically significant single‐nucleotide, indel, and copy number variants.

<table><thead><tr class="header"><th>Family ID</th><th>Gender</th><th>Current Age</th><th>Age at Initial MRI</th><th>Gene</th><th>Zygosity</th><th>Variant (GRCh37) &amp; Transcript ID</th><th>cDNA</th><th>Protein</th><th>rsID</th><th>gnomAD AF<a href="#acn350957-note-0005" data-ref-type="fn">1</a></th><th>Max AF<a href="#acn350957-note-0006" data-ref-type="fn">2</a></th><th><p>SIFT/ Mutation</p><p>Taster<a href="#acn350957-note-0007" data-ref-type="fn">3</a></p></th><th>Variant Classification</th><th>ACMG Criteria<a href="#acn350957-note-0008" data-ref-type="fn">4</a></th></tr></thead><tbody><tr class="odd"><td>Novel Gene (<em>n</em> = 4)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>LD_0246</td><td>M</td><td>8 Y</td><td>11 M</td><td><em>H3F3B</em></td><td><p>Het.,</p><p><em>de novo</em></p></td><td><p>17‐73774722‐G‐C</p><p>ENST00000254810</p></td><td>c.365C&gt; G</td><td>Pro122Arg</td><td>N/A</td><td>0.0000</td><td>0.0000</td><td>N/A/ DC</td><td>Pathogenic</td><td>PS2, PM2, PP3</td></tr><tr class="odd"><td>LD_0500</td><td>M</td><td>6 Y</td><td>23 M</td><td><em>AIFM1</em></td><td><p>Hemi.,</p><p><em>de novo</em></p></td><td><p>X‐129274569‐G‐A</p><p>ENST00000287295</p></td><td>c.720C&gt; T</td><td>Asp240Asp</td><td>N/A</td><td>0.0000</td><td>0.0000</td><td>N/A/ N/A</td><td>Pathogenic</td><td>PS2, PS3, PM2</td></tr><tr class="even"><td>LD_0527</td><td>M</td><td>8 Y</td><td>UNK</td><td><em>NKX6‐2</em></td><td>Hom.</td><td><p>10‐134598648‐C‐TA</p><p>ENST00000368592</p></td><td>c.606delGinsTA</td><td>Lys202fs</td><td>N/A</td><td>0.0000</td><td>0.0000</td><td>N/A/ N/A</td><td>Likely pathogenic</td><td>PVS1, PM2</td></tr><tr class="odd"><td>LD_0807</td><td>F</td><td>17 Y</td><td>12 Y</td><td><em>SNORD118</em></td><td>Het. (m)</td><td><p>17‐8076848‐A‐C</p><p>ENST00000363593</p></td><td>n.58 T&gt; G</td><td>N/A</td><td>N/A</td><td>0.0000</td><td>0.0000</td><td>N/A/ N/A</td><td>VUS</td><td>PM2, PM3, PP4, BP6</td></tr><tr class="even"><td>Het. (p)</td><td><p>17‐8076762‐G‐A</p><p>ENST00000363593</p></td><td>n. <sup>*</sup>9C&gt; T</td><td>N/A</td><td>N/A</td><td>0.001907</td><td>0.001907</td><td>N/A/ N/A</td><td>VUS</td><td>PM2, PM3, PP4, BP6</td><td></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>Intronic (<em>n</em> = 1)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>LD_0393</td><td>F (3) &amp; M (1)</td><td>N/A</td><td>N/A</td><td><em>CSF1R</em></td><td>Hom.</td><td><p>5‐149440309‐CT‐</p><p>ENST00000286301</p></td><td>c.1969 + 115_1969+116delAG<a href="#acn350957-note-0009" data-ref-type="fn">5</a></td><td>Pro658Serfs<sup>*</sup>24</td><td>N/A</td><td>0.0000</td><td>0.0000</td><td>N/A/ N/A</td><td>Likely pathogenic</td><td>PS3, PM2, PP1</td></tr><tr class="odd"><td>MT‐DNA (<em>n</em> = 1)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>LD_0725</td><td>F</td><td>21 Y</td><td>1 Y</td><td><em>MT‐TL1</em></td><td>Het. (m)</td><td><p>MT‐3243‐A‐G</p><p>ENST00000386347</p></td><td>n.14A&gt; G</td><td>N/A</td><td>rs199474657</td><td>N/A</td><td>N/A</td><td>N/A/ N/A</td><td>Pathogenic</td><td>PS1, PS3, PP3, PP4</td></tr><tr class="odd"><td>Challenging Variants (<em>n</em> = 2)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>LD_0315</td><td>M</td><td>7 Y</td><td>19 M</td><td><em>DARS2</em></td><td>Het. (p)</td><td><p>1‐173797450‐T‐CC</p><p>ENST00000361951</p></td><td>c.228‐21delTinsCC</td><td>N/A</td><td>rs528772984</td><td>0.000021</td><td>0.002</td><td>N/A/ N/A</td><td>Likely pathogenic</td><td>PS3, PM1</td></tr><tr class="odd"><td>Het. (m)</td><td><p>1‐173797537‐G‐T</p><p>ENST00000361951</p></td><td>c.294G&gt;T<a href="#acn350957-note-0010" data-ref-type="fn">6</a></td><td>Glu98Asp</td><td>N/A</td><td>0.0000</td><td>0.0000</td><td>T/ DC</td><td>Likely pathogenic</td><td>PS3, PM2, PP2, PP3</td><td></td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>LD_0617</td><td>F</td><td>7 Y</td><td>2 Y</td><td><em>GJC2</em></td><td>Het. (p)</td><td><p>1‐228346388‐C‐GCCTCCGCCCCCG</p><p>ENST00000366714</p></td><td>c.916_928dupGCCTCCGCCCCCG</td><td>Ala310fs</td><td>N/A</td><td>0.0000</td><td>0.0000</td><td>N/A/ N/A</td><td>Pathogenic</td><td>PVS1, PM2, PP4</td></tr><tr class="odd"><td>Het. (m)</td><td><p>1‐ 228345662‐A‐G</p><p>ENST00000366714</p></td><td>c.203A&gt; G</td><td>Tyr68Cys</td><td>rs1031720654</td><td>0.0000</td><td>0.0000</td><td>D/ DC</td><td>Likely pathogenic</td><td>PM2, PM3, PP3, PP4</td><td></td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>Improved Pipeline/ Separate study novel gene (<em>n</em> = 4)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>LD_0162</td><td>M &amp; M</td><td>Deceased</td><td>3 Y</td><td><em>HIKESHI</em></td><td>Hom.</td><td><p>11‐86017416‐G‐C</p><p>ENST0000027843</p></td><td>c.160G&gt; C</td><td>Val54Leu</td><td>rs202003795</td><td>0.0001299</td><td>0.0002</td><td>D/ DC</td><td>Likely pathogenic</td><td>PS1, PM1, PP1, PP4, PP5</td></tr><tr class="even"><td>LD_0579</td><td>M</td><td>5 Y</td><td>5 M</td><td><em>L1CAM</em></td><td>Hemi. (m)</td><td><p>X‐153135278‐A‐T</p><p>ENST00000264161</p></td><td>c.1103T&gt; A</td><td>Ile368Asn</td><td>N/A</td><td>0.0000</td><td>0.0000</td><td>D/ DC</td><td>Likely pathogenic</td><td>PM1, PM2, PP2, PP3</td></tr><tr class="odd"><td>LD_0808</td><td>M</td><td>6 Y</td><td>18 M</td><td><em>SPATA5</em></td><td>Het. (p)</td><td><p>4‐123855300‐G‐A</p><p>ENST00000274008</p></td><td>c.554G&gt; A</td><td>Gly185Glu</td><td>rs753587518</td><td>0.0000253</td><td>0.0002</td><td>D/ DC</td><td>Likely pathogenic</td><td>PM2,PM3, PP2, PP3, PP4</td></tr><tr class="even"><td>Het. (m)</td><td><p>4‐123949348‐G‐C</p><p>ENST00000274008</p></td><td>c.1877G&gt; C</td><td>Trp626Ser</td><td>rs375343753</td><td>0.0000122</td><td>0.0000</td><td>D/ DC</td><td>Likely pathogenic</td><td>PM2, PM5, PP3, PP4, PP5</td><td></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>Clinically Resolved</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>LD_0587</td><td>M</td><td>9 Y</td><td>9 M</td><td><em>KDM5C</em></td><td>Hemi. (m)</td><td><p>X‐53226186‐C‐A</p><p>ENST00000375401</p></td><td>c.2663G&gt; T</td><td>Arg888Leu</td><td>rs375850872</td><td>0.0000144</td><td>0.0001</td><td>D/ P</td><td>VUS</td><td>PM2, PP3</td></tr></tbody></table>

<table><thead><tr class="header"><th>Copy Number Variants</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></tr></thead><tbody><tr class="odd"><td>LD_0498</td><td>F</td><td>9 Y</td><td>4 Y</td><td><p>Chr10:27500219‐27507820</p><p>Precise breakpoints as determined by Sanger:</p><p>c.626‐689_937‐235delins936 + 1075_936+1230inv</p></td><td>7,601</td><td>Deletion</td><td>Homozygous</td><td><em>ACBD5</em></td><td>N/A</td></tr><tr class="even"><td>LD_0594</td><td>M</td><td>11 Y</td><td>2 M</td><td>ChrX:24642417‐25038408</td><td>395,991</td><td>Duplication</td><td>Het., maternally inherited</td><td><em>ARX, POLA1, PCYT1B</em></td><td>N/A</td></tr><tr class="odd"><td>LD_0671</td><td>M</td><td>5 Y</td><td>18 M</td><td>Chr2:200222207‐200243660</td><td>21,453</td><td>Deletion</td><td>De novo</td><td><em>SATB2</em></td><td>Glass Syndrome (OMIM:612313)</td></tr></tbody></table>

Key: M -- Month; Y -- Years; UNK -- Unknown; MT-- mitochondrial; Het. -- heterozygous; Hemi. -- Hemizygous; Hom. ‐ Homozygous; N/A -- Not available; AF -- allele frequency.

Total allele frequency in Genome Aggregation Database (gnomAD) dataset.

Maximum reported allele frequency for any single subpopulation represented in ExAC, 1000 Genomes, or Exome Variant Server datasets.

DC -- Disease‐Causing; DA -- Disease‐Causing Automatic; D -- Damaging; T -- Tolerated

ACMG criteria upon which classification is based

Variant shown in Guo et al. 2019 to result in inclusion of a novel 99nt pseudo‐exon, with an in‐frame stop codon p.(P658Sfs\*24) resulting in nonsense‐mediated decay.

Variant shown to result in *DARS2* Exon 3 skipping. See Appendix S1.

John Wiley & Sons, Ltd

Since our initial study, more than 1,200 new gene--disease relationships have been described, and studies have shown increases of up to 10% in diagnostic yield with reanalysis within 24--36 months.[10](#acn350957-bib-0010){ref-type="ref"} Reanalysis in the context of recently published literature (and associated annotation pipelines) allowed resolution of an additional eight cases. These included a de novo missense variant in *H3F3B* (OMIM:601058) (LD_0246)*,* [11](#acn350957-bib-0011){ref-type="ref"} a hemizygous, synonymous variant in *AIFM1* (OMIM:300169) (LD_0500),[12](#acn350957-bib-0012){ref-type="ref"} and biallelic variants in *HIKESHI* (OMIM:614908) (LD_0162),[13](#acn350957-bib-0013){ref-type="ref"} *NKX6‐2* (OMIM:605955) (LD_0527)*,* [14](#acn350957-bib-0014){ref-type="ref"} and *SPATA5* (OMIM:613940) (LD_0808),[15](#acn350957-bib-0015){ref-type="ref"} all previously associated with prominent white matter disease in multiple affected individuals. Affected individuals in families LD_0579 and LD_0587 had variants in genes previously implicated in neurologic syndromes where improvements to our analysis pipeline or improved phenotypic understand permitted a diagnosis or prioritized a high confidence candidate, in *L1CAM* (OMIM:308840)[16](#acn350957-bib-0016){ref-type="ref"} and *KDM5C* (OMIM:314690),[17](#acn350957-bib-0017){ref-type="ref"} respectively. White matter abnormalities are a rare association with *L1CAM‐*related disorder.[16](#acn350957-bib-0016){ref-type="ref"} LD_0587 has a clinical presentation with intellectual disability, epilepsy, aggressive behavior, and macrocephaly, all consistent features of *KDM5C*‐related disorder and is classified as clinically resolved but the identified variant lacks definitive proof to be classified as likely pathogenic or pathogenic.[17](#acn350957-bib-0017){ref-type="ref"} This case was not included in overall numbers of definitively resolved cases as this variant remains a variant of uncertain significance per the ACMG criteria. Finally, causal nonprotein‐coding variants were identified in *SNORD118* (OMIM:616663), confirming a clinical diagnosis of leukoencephalopathy with calcifications and cysts (OMIM:614561) in LD_0807.[18](#acn350957-bib-0018){ref-type="ref"} *SNORD118* variants were found as part of a targeted cohort study and concomitantly found in our genome sequencing cohort.[18](#acn350957-bib-0018){ref-type="ref"}

In two individuals, genome sequencing revealed variants not identified on exome sequencing analysis due to lack of variant annotation or stringent filtering. For LD_0725, genome sequencing revealed a mitochondrial DNA variant, m.3243A\>G in *MT‐TL1* (OMIM:590050), carried on 42% of reads in the affected individual and 15% of the maternal reads. This variant has been previously associated with mitochondrial encephalomyopathy, lactic acidosis, and stroke‐like episodes (MELAS \[OMIM:540000\]). LD_0315 had biallelic variants in *DARS2* (OMIM:610956), associated with leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL \[OMIM:611105\]). An intronic variant, c.228‐21delTinsCC, p.(Arg76Serfs\*5) that has been shown to affect mRNA splicing of *DARS2* with skipping of exon 3[19](#acn350957-bib-0019){ref-type="ref"} was found in *trans* with a previously unreported missense variant, c.294G\>T, p.(Glu98Asp). Stringent variant filtering performed during the prior exome sequencing analysis excluded this intronic variant and precluded a diagnosis.[1](#acn350957-bib-0001){ref-type="ref"} To confirm the predicted splicing change of intronic and exonic variants based on SpliceAI annotations,[20](#acn350957-bib-0020){ref-type="ref"} we generated a minigene splicing reporter assay (Appendix [S1](#acn350957-sup-0001){ref-type="supplementary-material"}), demonstrating each variant results in the skipping of exon 3 (Appendix [S1](#acn350957-sup-0001){ref-type="supplementary-material"}).

The remaining five cases were resolved due to the identification of variants not typically identifiable by exome sequencing. The first is related to a region that is technically difficult to assess. Biallelic variants were identified in LD_0617 in *GJC2* (OMIM:608803), causative of Pelizaeus‐Merzbacher‐like disease (PMLD \[OMIM:608804\]), a maternally inherited missense variant c.203A\>G, p.(Tyr68Cys), and a 13 base paternally inherited duplication c.916_928dupGCCTCCGCCCCCG, p.(Ala310fs). The duplication was previously undetected by exome sequencing due to a lack of coverage as it lies in the middle of a 110 nucleotide block of a \~ 95% GC‐rich region (Fig. [1](#acn350957-fig-0001){ref-type="fig"}B).[1](#acn350957-bib-0001){ref-type="ref"} The c.916_928dupGCCTCCGCCCCCG *GJC2* variant called by genome sequencing was supported by six of 19 genome sequencing reads covering the position (Fig. [1](#acn350957-fig-0001){ref-type="fig"}C), and was confirmed by Sanger sequencing (Fig. [1](#acn350957-fig-0001){ref-type="fig"}D).

In family LD_0393, genome sequencing revealed a homozygous intronic variant, c.1969+115_1969+116delAG in *CSF1R* (OMIM:164770). Heterozygous *CSF1R* variants are associated with another leukodystrophy, hereditary diffuse leukoencephalopathy with spheroids (OMIM:221820). This biallelic variant affects a cryptic splice site and results in the inclusion of a novel 99nt pseudo‐exon, with an in‐frame stop codon p.(Pro658Serfs\*24) resulting in nonsense‐mediated decay of the truncated protein. These individuals were found to have a novel syndrome due to biallelic variants in *CSF1R* characterized by brain malformation and skeletal dysplasia, reported in Guo et al. (2019).[21](#acn350957-bib-0021){ref-type="ref"}

Genome sequencing CNV analysis provided a diagnosis in three affected individuals (Table [1](#acn350957-tbl-0001){ref-type="table"}). LD_0498 was found to have impaired peroxisomal β‐oxidation of C26:0 and genome sequencing revealed a homozygous, 7.5kb deletion in *ACBD5* (OMIM:616618) causing loss of exons 7 and 8, confirmed by Sanger sequencing.[22](#acn350957-bib-0022){ref-type="ref"} LD_0594 was found to have an X‐linked 396kb duplication covering *ARX* (OMIM: 300382), previously associated with a broad spectrum of neuroimaging abnormalities and early infantile epileptic encephalopathy (OMIM:308350). LD_0671 was found to harbor a 21kb de novo deletion encompassing a region in chromosome 2 covering *SATB2* (OMIM:608148), previously associated with Glass syndrome (OMIM:612313).[23](#acn350957-bib-0023){ref-type="ref"}

Discussion {#acn350957-sec-0007}
==========

Of the original 191 families examined in this cohort, 101 received a definitive diagnosis using enzymatic, biochemical, or single gene molecular approaches (53%). Nineteen families were subsequently lost to follow‐up, leaving 71 families able to be tested by NGS. Thirty cases were solved by exome sequencing,[1](#acn350957-bib-0001){ref-type="ref"} and in this study, genome sequencing established a diagnosis in an additional 14 families yielding a 20% improvement, and an overall diagnostic efficacy of NGS of genome or exome sequencing increased to 44/71 (62%) and in total resolution of 145/172 (84%) of the original testable cohort.

Reanalysis by genome sequencing also led to the identification of variants in recently described disease genes *AIFM1*,[12](#acn350957-bib-0012){ref-type="ref"} *HIKESHI,* [13](#acn350957-bib-0013){ref-type="ref"} *H3F3B,* [11](#acn350957-bib-0011){ref-type="ref"} *NKX6‐2,* [14](#acn350957-bib-0014){ref-type="ref"} and *SPATA5,* [15](#acn350957-bib-0015){ref-type="ref"} and genes missed in the previous analysis (*L1CAM*). This is consistent with multiple recent studies that have shown increases of up to 10% in diagnostic yield with reanalysis within 24--36 months.[10](#acn350957-bib-0010){ref-type="ref"} Improvements in variant annotation and filtering detected variants in mitochondrial DNA and intronic regions proximal to captured exons. It is expected that these would have been identified on exome sequencing if performed with current testing modalities.

Genome sequencing findings improved the overall diagnostic yield in this cohort by \~11% (5/44 cases solved by NGS), through the detection of variants in GC‐rich regions, deep intronic variants, and CNVs. As sequencing assays and associated informatic pipelines improve, some of these variant types may be detected by exome sequencing. In our exome analysis, however, these variants were not found due to limitations of either sequencing or analysis, some of which will be difficult to overcome due to limitations of the assay (e.g. GC‐rich regions) or the ability of exome to accurately detect large genomic alterations in single cases.

Our study lends support to a previous study that suggested that currently up to 80% of white matter disorders may be able to be solved.[2](#acn350957-bib-0002){ref-type="ref"} Notably, no recurring diagnoses were made in the current cohort of *n* = 41, and only a minority across all tiers of NGS testing (20%) were associated with canonical leukodystrophy genes. These data indicate that only a fraction of affected individuals would achieve a diagnosis using targeted testing approaches, including panels of classically defined leukodystrophy genes now in widespread use. An established diagnostic workflow for laboratory and genetic testing in combination with MRI pattern recognition[24](#acn350957-bib-0024){ref-type="ref"} suggests that if initial biochemical and enzymatic testing is not confirmatory and if the MRI does not fit an established leukodystrophy, broad‐based NGS testing should be implemented. Our data support this approach, favoring genome sequencing over exome sequencing.
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